IN8bio, Inc. (INAB) Stock Score, Valuation & Financial Research

IN8bio, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for INAB

IN8bio, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.39. These figures are a research snapshot, not a buy or sell recommendation.

What IN8bio, Inc. does

IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

IN8bio is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and strategic financing to fund the research, development, and clinical trials of its proprietary gamma-delta T cell therapy and T cell engager platforms.

Products and services

  • The company develops gamma-delta T cell therapies and T cell engagers (TCEs) for the treatment of cancer and autoimmune diseases, including product candidates such as INB-100, INB-200, INB-400, and INB-619.

Brands and product families

  • DeltEx — Proprietary platform for gamma-delta T cell product candidates. Source

Customer types

Clinical trial patients.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations (CMOs) — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials and product candidates. Source

Competitors and product-market comparisons

  • Blinatumomab (Amgen) — A commercial CD19-targeting engager used as a benchmark for efficacy in preclinical models. Source
  • Mosunetuzumab (Roche/Genentech) — A commercial CD20-targeting engager used as a benchmark for efficacy in preclinical models. Source

Business strengths to evaluate

  • Proprietary DeltEx platform for gamma-delta T cell therapies Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on third-party manufacturers for clinical supply Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

INAB financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.39
Market capitalization:
13.33M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -18.67M
Free cash flow:
USD -12.71M
Cash:
USD 17.96M
Total debt:
USD 2.18M
EPS:
USD -1.87

What stands out

  • Free cash flow is USD -12.71M, negative for the stored period.
  • The balance sheet shows USD 17.96M of cash versus USD 2.18M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 15.78M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for INAB

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can INAB fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is INAB likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for INAB to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of INAB's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research INAB

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.